Releasing the true power of protease inhibitors.
Atazanavir is a potent, novel and highly selective inhibitor of the HIV-1 protease, with a low pill burden and once-daily dosing. Clinical studies have shown atazanavir to be the first protease inhibitor (PI) to have equivalent efficacy to efavirenz over a 48-week period of follow-up in PI-treatment-naïve patients. Loss of susceptibility to atazanavir in PI-naïve patients occurs infrequently and is not associated with cross-resistance to other PIs. In clinical trials, atazanavir has shown better gastrointestinal tolerability than other PIs. Also, unlike other PIs, atazanavir has been associated with decreases, or only minimal increases, in lipid parameters such as low-density lipoprotein cholesterol and triglycerides.
Raffi
F
F
Infectious Diseases Department, University Hospital, Nantes, France. francois.raffi@wanadoo.fr
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D048588:Benzoxazines; D003521:Cyclopropanes; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D010078:Oxazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D010078:Oxazines; D011725:Pyridines; D000069446:Atazanavir Sulfate; C098320:efavirenz